ACM
VVOS icon

Archon Capital Management’s Vivos Therapeutics VVOS Stock Holding History

Archon Capital Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,600
Closed -$1.06M – 36
2021
Q2 		$1.06M Buy
+8,600
New +$1.4M 0.12% 36

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Archon Capital Management's VVOS Position: Q3 2021 in Review

Archon Capital Management sold out of Vivos Therapeutics (VVOS) in Q3 2021, closing a stake of 8,600 shares — an estimated $1.06M sold.

Archon Capital Management first reported a position in VVOS in Q2 2021 and held it in 1 quarter. The position peaked at $1.06M in Q2 2021. 37 funds tracked by Wall St. Rank hold VVOS as of Q3 2021.

  • Archon Capital Management reported no remaining Vivos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Archon Capital Management sold 8,600 Vivos Therapeutics shares in Q3 2021, an estimated $1.06M.
  • Archon Capital Management first reported a position in Vivos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Archon Capital Management's Vivos Therapeutics position peaked at $1.06M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2021.

Based on Archon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.